Capricor Therapeutics (CAPR) Tops Q1 EPS by 1c

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of $0.31, $0.01 better than the analyst estimate of $0.30. Revenue for the quarter came in at $2.98 million versus the consensus estimate of $500 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Carvana's share gains and production growth remain on track, Wells Fargo says
• Infleqtion raises Q2 revenue to $13.5M after contract restatement